Harini Ramalingam1, Matanel Yheskel2, Vishal Patel3. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States of America. 2. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States of America; Medical Scientist Training Program (MSTP), Albert Einstein College of Medicine, New York, NY, United States of America. 3. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States of America. Electronic address: vishald.patel@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: microRNAs (miRNAs) are a class of small, evolutionarily conserved, non-coding RNAs (ncRNAs) that function as inhibitors of post-transcriptional mRNA expression. They are implicated in the pathogenesis of numerous diseases, including many common kidney conditions. In this review, we focus on how miRNAs impact autosomal dominant polycystic kidney disease (ADPKD) progression. We also discuss the feasibility of the emerging novel antisense oligonucleotides (ASOs) drug class, which includes anti-miRNA drugs, for the treatment of ADPKD. RECENT FINDINGS: Aberrant miRNA expression is observed in multiple PKD murine models and human ADPKD samples. Gain and loss-of-function studies have directly linked dysregulated miRNA activity to kidney cyst growth. The most comprehensively studied miRNA in PKD is the miR-17 family, which promotes PKD progression through the rewiring of cyst metabolism and by directly inhibiting PKD1 and PKD2 expression. This discovery has led to the development of an anti-miR-17 drug for ADPKD treatment. Other miRNAs such as miR-21, miR-193, and miR-214 are also known to regulate cyst growth by modulating cyst epithelial apoptosis, proliferation, and interstitial inflammation. SUMMARY: miRNAs have emerged as novel pathogenic regulators of ADPKD progression. Anti-miR-based drugs represent a new therapeutic modality to treat ADPKD patients.
PURPOSE OF REVIEW: microRNAs (miRNAs) are a class of small, evolutionarily conserved, non-coding RNAs (ncRNAs) that function as inhibitors of post-transcriptional mRNA expression. They are implicated in the pathogenesis of numerous diseases, including many common kidney conditions. In this review, we focus on how miRNAs impact autosomal dominant polycystic kidney disease (ADPKD) progression. We also discuss the feasibility of the emerging novel antisense oligonucleotides (ASOs) drug class, which includes anti-miRNA drugs, for the treatment of ADPKD. RECENT FINDINGS: Aberrant miRNA expression is observed in multiple PKDmurine models and human ADPKD samples. Gain and loss-of-function studies have directly linked dysregulated miRNA activity to kidney cyst growth. The most comprehensively studied miRNA in PKD is the miR-17 family, which promotes PKD progression through the rewiring of cyst metabolism and by directly inhibiting PKD1 and PKD2 expression. This discovery has led to the development of an anti-miR-17 drug for ADPKD treatment. Other miRNAs such as miR-21, miR-193, and miR-214 are also known to regulate cyst growth by modulating cyst epithelial apoptosis, proliferation, and interstitial inflammation. SUMMARY: miRNAs have emerged as novel pathogenic regulators of ADPKD progression. Anti-miR-based drugs represent a new therapeutic modality to treat ADPKD patients.
Authors: Andrew J Streets; Tajdida A Magayr; Linghong Huang; Laura Vergoz; Sandro Rossetti; Roslyn J Simms; Peter C Harris; Dorien J M Peters; Albert C M Ong Journal: Am J Physiol Renal Physiol Date: 2017-01-11
Authors: John F Bertram; Rebecca N Douglas-Denton; Boucar Diouf; Michael D Hughson; Wendy E Hoy Journal: Pediatr Nephrol Date: 2011-05-22 Impact factor: 3.714
Authors: G D Plowman; J M Culouscou; G S Whitney; J M Green; G W Carlton; L Foy; M G Neubauer; M Shoyab Journal: Proc Natl Acad Sci U S A Date: 1993-03-01 Impact factor: 11.205
Authors: Scott J Harvey; George Jarad; Jeanette Cunningham; Seth Goldberg; Bernhard Schermer; Brian D Harfe; Michael T McManus; Thomas Benzing; Jeffrey H Miner Journal: J Am Soc Nephrol Date: 2008-09-05 Impact factor: 10.121
Authors: Luis Alberto Bravo Vázquez; Mariana Yunuen Moreno Becerril; Erick Octavio Mora Hernández; Gabriela García de León Carmona; María Emilia Aguirre Padilla; Samik Chakraborty; Anindya Bandyopadhyay; Sujay Paul Journal: Molecules Date: 2021-12-30 Impact factor: 4.411
Authors: Luis M Ruiz-Manriquez; Schoenstatt Janin Ledesma Pacheco; Daniel Medina-Gomez; Andrea G Uriostegui-Pena; Carolina Estrada-Meza; Anindya Bandyopadhyay; Surajit Pathak; Antara Banerjee; Samik Chakraborty; Aashish Srivastava; Sujay Paul Journal: Genes (Basel) Date: 2022-01-22 Impact factor: 4.096
Authors: Fernando Cartón-García; Cassondra Jeanette Saande; Daniel Meraviglia-Crivelli; Rafael Aldabe; Fernando Pastor Journal: Biomedicines Date: 2021-03-16